Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AOTI, Inc. ( (GB:AOTI) ) has shared an announcement.
AOTI, Inc. announced the granting of performance share awards to its CFO, Jayesh Pankhania, under its Long Term Incentive Plan (LTIP). These awards are contingent on achieving specific performance conditions over a three-year period, including revenue growth and total shareholder return. This move aims to align the CFO’s interests with the company’s long-term growth objectives and shareholder value, highlighting AOTI’s commitment to incentivizing key management to drive operational success and competitive positioning in the medical technology sector.
More about AOTI, Inc.
AOTI, Inc. is a medical technology group focused on the durable healing of wounds and prevention of amputations. The company, founded in 2006 with operations in Oceanside, California, and Galway, Ireland, provides solutions aimed at reducing healthcare costs and improving patient quality of life through its patented non-invasive Topical Wound Oxygen (TWO2®) therapy. This therapy has been shown to significantly reduce the recurrence of Diabetic Foot Ulcers, hospitalizations, and amputations, and is approved by regulatory bodies including the FDA and CE Mark.
YTD Price Performance: -15.44%
Average Trading Volume: 22,610
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £122.3M
Find detailed analytics on AOTI stock on TipRanks’ Stock Analysis page.